The National Pancreatic Cyst Registry Study1,4 

  • Integrated Molecular Pathology (PancraGEN®) is intended to be an adjunct to first line testing
  • When used as adjuvant to EUS/FNA testing, PancraGEN® can reduce the number of unnecessary surgeries while also providing assurance in surveillance strategies of patients
  • Real world intervention and surveillance decisions were highly associated with PancraGEN® diagnostic recommendation
  • PancraGEN® diagnoses were more predictive of real world management decisions, benefiting overall patient outcomes more than sole reliance on ICG criteria